Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Sun Pharmaceutical Industries Europe B.V., Polarisavenue 87, 2132 JH Hoofddorp, The Netherlands
Intravenous administration of Pantoprazole is recommended only if oral administration is not appropriate. Data are available on intravenous use for up to 7 days. Therefore, as soon as oral therapy is possible, treatment with Pantoprazole i.v. should be discontinued and 40 mg pantoprazole p.o. should be administered instead.
The recommended intravenous dose is one vial of Pantoprazole (40 mg pantoprazole) per day.
For the long-term management of Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions patients should start their treatment with a daily dose of 80 mg Pantoprazole. Thereafter, the dose can be titrated up or down as needed using measurements of gastric acid secretion to guide. With doses above 80 mg daily, the dose should be divided and given twice daily. A temporary increase of the dose above 160 mg pantoprazole is possible but should not be applied longer than required for adequate acid control.
In case a rapid acid control is required, a starting dose of 2 × 80 mg Pantoprazole is sufficient to manage a decrease of acid output into the target range (<10 mEq/h) within one hour in the majority of patients.
The safety and efficacy of Pantoprazole in children aged under 18 years have not been established. Therefore, Pantoprazole is not recommended for use in patients below 18 years of age.
Currently available data are described in section 5.2 but no recommendation on a posology can be made.
A daily dose of 20 mg pantoprazole (half a vial of 40 mg pantoprazole) should not be exceeded in patients with severe liver impairment (see section 4.4).
No dose adjustment is necessary in patients with impaired renal function.
No dose adjustment is necessary in elderly patients.
This medicine should be administered by a healthcare professional and under appropriate medical supervision.
A ready-to-use solution is prepared in 10 ml of sodium chloride 9 mg/ml (0.9%) solution for injection. For instructions for preparation of the medicinal product before administration, see section 6.6. The prepared solution may be administered directly or may be administered after mixing it with 100 ml sodium chloride 9 mg/ml (0.9%) solution for injection or glucose 55 mg/ml (5%) solution for injection.
After preparation the solution must be used within 12 hours.
The medicinal product should be administered intravenously over 2-15 minutes.
For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6.
There are no known symptoms of overdose in man.
Systemic exposure with up to 240 mg administered intravenously over 2 minutes were well tolerated.
Pantoprazole is extensively protein bound, it is not readily dialyzable.
In the case of overdose with clinical signs of intoxication, apart from symptomatic and supportive treatment, no specific therapeutic recommendations can be made.
Shelf life: 18 months.
After reconstitution, or reconstitution and dilution, chemical and physical in-use stability has been demonstrated for 12 hours at 25°C.
From a microbiological point of view, unless the method of opening and dilution precludes the risk of microbial contamination, the product should be used immediately.
If not used immediately, in-use storage times and conditions are the responsibility of the user.
Store below 25°C.
For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.
10 ml type-I tubular colourless glass vial with grey bromobutyl rubber stopper, sealed with a red flip-off tear-off aluminium seal.
Pantoprazole 40 mg powder for solution for injection is supplied in packs containing 1, 5, 10 or 50 vials.
Not all pack sizes may be marketed.
A ready-to-use solution is prepared by injecting 10 ml of sodium chloride 9 mg/ml (0.9 ) solution for injection into the vial containing the powder. The appearance of the product after reconstitution is a clear colorless solution, practically free from particles. This solution may be administered directly or may be administered after mixing it with 100 ml sodium chloride 9 mg/ml (0.9) solution for injection or glucose 55 mg/ml (5%) solution for injection. Glass or plastic containers should be used for dilution.
Pantoprazole should not be prepared or mixed with solvents other than those stated.
The medicine should be administered intravenously over 2-15 minutes.
The contents of the vial are for single use only. Any product that has remained in the container or the visual appearance of which has changed (e.g. if cloudiness or precipitation is observed) should be disposed of in accordance with local requirements.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
